AYTU BIOPHARMA, INC issued warrant to institutional investors for exchange of existing warrants for amended warrants.
“On March 31, 2026, the Company and the Investors, as applicable, entered into (i) an Amended and Restated June 2023 Prefunded Warrant (“Amended 2023 Prefunded Warrant”), (ii) an Amended and Restated June 2023 Tranche A Warrant (“Amended 2023 Tranche A Warrant”) and (iii) an Amended and Restated June 2025 Prefunded Warrant (“Amended 2025 Prefunded Warrant”), pursuant to which the Company canceled the previously issued Warrants and issued to the Investors, as applicable, an Amended 2023 Prefunded Warrant, an Amended 2023 Tranche A Warrant and an Amended 2025 Prefunded Warrant, with revised Blockers.”
Material Agreements
AYTU BIOPHARMA, INC amended Amended 2023 Prefunded Warrant with certain institutional investors (effective 2026-03-31).
“the Company and the Investors, as applicable, entered into (i) an Amended and Restated June 2023 Prefunded Warrant ("Amended 2023 Prefunded Warrant"), (ii) an Amended and Restated June 2023 Tranche A Warrant ("Amended 2023 Tranche A Warrant") and (iii) an Amended and Restated June 2025 Prefunded Warrant ("Amended 2025 Prefunded Warrant"), pursuant to which the Company canceled the previously issued Warrants and issued to the Investors, as applicable, an Amended 2023 Prefunded Warrant, an Amended 2023 Tranche A Warrant and an Amended 2025 Prefunded Warrant, with revised Blockers”
Debt Financings
AYTU BIOPHARMA, INC amended revolving credit of $1.5 million incremental advance with Eclipse Business Capital LLC at SOFR plus 5.50% maturing June 12, 2029.
“extended the revolving credit facility (the “Eclipse Revolving Loan”) maturity date to June 12, 2029, and increased the potential maximum borrowing base pursuant to a $1.5 million incremental advance (the “Eclipse Incremental Advance”), at an interest rate of the SOFR plus 5.50%”
Debt Financings
AYTU BIOPHARMA, INC amended term loan of outstanding principal amount of $13.0 million with Eclipse Business Capital LLC maturing June 12, 2029.
“extended the term loan (the “Eclipse Term Loan”) maturity date to June 12, 2029, and increased the Eclipse Term Loan resulting in an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment”
Ryan Selhorn was appointed as Chief Financial Officer, Corporate Secretary and Treasurer at AYTU BIOPHARMA, INC.
“On November 11, 2024, the board of directors of the Company (the " Board ") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.”
Mark K. Oki was terminated as Chief Financial Officer at AYTU BIOPHARMA, INC.
“On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.”
Earnings Releases
AYTU BIOPHARMA, INC reported fiscal 2024 third quarter results: revenue $18.0 million, net income $2.9 million, EPS $0.52 per share.
“on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter. Q3 2024 Highlights ● Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment. ● ADHD Portfolio (Adzenys XR-ODT® and”
Earnings Releases
AYTU BIOPHARMA, INC reported fiscal 2024 second quarter results: revenue $22.9 million, net income $0.2 million, or $0.04 per share, EPS $0.04 per share.
“on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter. Q2 2024 Highlights ● Consolidated net revenue was $22.9 million, compared to $26.3 million in the prior year period. The decrease is primarily due to the planned wind down of the Company's Consumer Health Segment. ● ADHD Portfolio (Adzenys”
Material Agreements
AYTU BIOPHARMA, INC entered into Commercial Manufacturing Services Agreement with Halo Pharmaceutical, Inc. (effective 2023-11-13).
“On November 13, 2023, Aytu BioPharma, Inc. (the “ Company ”) entered into a Commercial Manufacturing Services Agreement (the “ Agreement ”), with Halo Pharmaceutical, Inc. (“ Halo ”), pursuant to which Halo will manufacture Adzenys XR ODT® and Cotempla XR ODT® products for the Company at Halo’s manufacturing facility.”
Earnings Releases
AYTU BIOPHARMA, INC reported fiscal quarter ended September 30, 2023 results: revenue $22.1 million, net income Net loss during Q1 2024 was $8.1 million, or $1.48 per share, EPS $1.48 per share.
“operational results for the first quarter of fiscal 2024 ended September 30, 2023. Q1 2024 Commercial Highlights (3 months ending September 30, 2023) · Total net revenue was $22.1 million, compared to $27.7 million. The change is primarily due to the planned wind down of the Company’s Consumer Health segment and the associated decrease in Consumer Health revenue.”
Christopher Brooke resigned as Chief Operating Officer at AYTU BIOPHARMA, INC.
“On October 3, 2023, Christopher Brooke resigned as Chief Operating Officer of Aytu BioPharma, Inc. (the “Company”), effective October 13, 2023, to pursue another opportunity at a development-stage biotechnology company.”
Earnings Releases
AYTU BIOPHARMA, INC reported the fiscal year ended June 30, 2023 results: revenue $107.4 million, net income $17.1 million, EPS $5.11 per share.
“were $23.0 million at June 30, 2023 compared to $19.2 million at March 31, 2023. FY 2023 Commercial Highlights (12 months ending June 30, 2023) ● Total net revenue was $107.4 million, an increase of 11% from $96.7 million in net revenue in FY 2022. ● Net revenue from the Company’s Rx segment was $73.8 million during FY 2023 compared to $61.1 million in FY”
Earnings Releases
AYTU BIOPHARMA, INC reported the fiscal quarter ended June 30, 2023 results: revenue $30.7 million, net income $2.5 million, EPS $0.59 per share.
“BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 million Record Q4 2023 total prescriptions increased 32% compared to Q4 2022 Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million”
Material Agreements
AYTU BIOPHARMA, INC entered into PAA with Maxim Group LLC (effective 2023-06-08).
“amed therein (the “Purchasers”), and a placement agency agreement (the “PAA”) with Maxim Group LLC (the “Placement Agent”), pursuant to which the Company agreed to issue and sell to investors in the offering (the”
Material Agreements
AYTU BIOPHARMA, INC entered into Purchase Agreement with certain investors valued at approximately $4 million (effective 2023-06-08).
“On June 8, 2023, Aytu BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein (the “Purchasers”)”
Abhinav Jain was appointed as Director at AYTU BIOPHARMA, INC.
“Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, the size of the Board will be increased from four (4) to five (5), and Abhinav Jain shall be appointed to the Board.”
Shareholder Votes
AYTU BIOPHARMA, INC shareholders approved Advisory vote on executive compensation at the 2023-05-18 meeting.
“The advisory vote on executive compensation was approved with 587,253 votes in favor, 383,698 votes against and 18,593 abstentions. There were 952,620 broker non-votes.”
Shareholder Votes
AYTU BIOPHARMA, INC shareholders approved Ratification of the appointment of Grant Thornton, LLC as independent registered public accounting firm at the 2023-05-18 meeting.
“The ratification of the appointment of Grant Thornton, LLC as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2023 was approved with 1,754,922 votes in favor, 132,135 votes against and 55,107 abstentions.”
Shareholder Votes
AYTU BIOPHARMA, INC shareholders approved Approval of the 2023 Equity Incentive Plan at the 2023-05-18 meeting.
“The approval of a new equity incentive plan for certain officers, directors, employees and other key personnel, the “2023 Equity Incentive Plan” was approved with 632,357 votes in favor, 352,359 votes against, and 4,828 abstentions. There were 952,620 broker non-votes.”
Shareholder Votes
AYTU BIOPHARMA, INC shareholders approved Election of five directors at the 2023-05-18 meeting.
“Our stockholders elected five members to our board of directors as follows:”
Earnings Releases
AYTU BIOPHARMA, INC reported the quarter ended March 31, 2023 results: revenue $22.7 million, net income $(7.2) million, EPS ($1.93) per share.
“Q3 2023 Commercial Highlights (3 months ending March 31, 2023) ● Total net revenue was $22.7 million, a decrease of 6% from the $24.2 million in net revenue in the year-ago quarter. Revenue during Q3 2023 was impacted by a one-time $1.2 million channel inventory adjustment due to an ADHD products price increase instituted on April 1, 2023. Excluding this impact, net revenue would have been $23.9 million, in-line with the year-ago quarter. ● Record total quarterly prescriptions of 153,452, a 32% increase over Q3 2022. ● Net revenue from the Company’s Rx segment was $13.8 million during Q3 2023 compared to $13.9 million in the year-ago quarter. o ADHD products (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue decreased by 21% to $8.3 million from $10.4 million in the year ago quarter. o Pediatric products (Poly-Vi-Flor®, Tri-Vi-Flor®, and Karbinal® ER) net revenue increased 81% to $5.3 million, from $2.9 million in the year-ago quarter. ● Consumer Health revenue during Q3 2023 was $8.9”
Material Agreements
AYTU BIOPHARMA, INC entered into Sublease Agreement with AMT Manufacturing Solutions, LLC (effective 2023-04-27).
“On April 27, 2023, Aytu BioPharma, Inc., through its wholly-owned subsidiary, Neos Therapeutics, LP, (“Aytu” or the “Company”) and AMT Manufacturing Solutions, LLC (“AMTMS”) entered into an agreement for Aytu to sublease 22,909 square feet of its manufacturing facility in Grand Prairie, Texas (“Sublease Agreement”).”
Debt Financings
AYTU BIOPHARMA, INC amended credit facility of No change in principal amount; amendment permitted the increase in revolving loan commitment under the Eclipse Facility with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P. as lenders, and Avenue Capital Management II, L.P. as administrative agent at Not specified maturing Not specified.
“In connection with the Eclipse Amendment, on March 24, 2023, the Obligors entered into the Second Amendment to Loan Documents (the “ Avenue Amendment ”) amending that certain Loan and Security Agreement dated January 26, 2022 (as amended by the First Amendment, dated October 25, 2022, the “ Avenue Agreement ”), by and among the Obligors, Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund II, L.P., as lenders (the “ Avenue Capital Lenders ”), and Avenue Capital Management II, L.P., as administrative agent (the “ Avenue Capital Agent ”). The Avenue Amendment, among other things, permitted the increase in revolving loan commitment provided by the Eclipse Lender under the Eclipse Facility as provided for in the Eclipse Amendment.”
Debt Financings
AYTU BIOPHARMA, INC amended revolving credit of Increase of $2,000,000 to revolving loan commitment, resulting in aggregate revolving facility size of $14,500,000 with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and the lenders party thereto at Not specified maturing Not specified.
“and the lenders party thereto (agent and such lenders, collectively, the “ Eclipse Lender ”). The Eclipse Amendment, among other things, provided for an aggregate increase of $2,000,000 to the Eclipse Lender’s commitment to make revolving loans from time to time to the Neos Obligors, resulting in an aggregate revolving facility size of $14,500,000 (such facility,”
Material Agreements
AYTU BIOPHARMA, INC amended Avenue Amendment with Avenue Venture Opportunities Fund II, L.P. and Avenue Capital Management II, L.P. (effective 2023-03-24).
“In connection with the Eclipse Amendment, on March 24, 2023, the Obligors entered into the Second Amendment to Loan Documents (the “ Avenue Amendment ”) amending that certain Loan and Security Agreement dated January 26, 2022 (as amended by the First Amendment, dated October 25, 2022, the “ Avenue Agreement ”)”
Material Agreements
AYTU BIOPHARMA, INC amended Eclipse Amendment with Eclipse Business Capital LLC, as agent, and the lenders party thereto valued at aggregate increase of $2,000,000 (effective 2023-03-24).
“On March 24, 2023, Aytu BioPharma, Inc. (“ Aytu ” or the “ Company ”) entered into an Amendment No. 4 (the “ Eclipse Amendment ”) to Loan and Security Agreement dated October 2, 2019”
Auditor Changes
AYTU BIOPHARMA, INC reported that prior financial statements should not be relied upon.
“and, accordingly, that such previously issued financial statements should no longer be relied upon”
Earnings Releases
AYTU BIOPHARMA, INC reported the quarter ended December 31, 2022 results: revenue $26.3 million.
“ --- EX-99.1 (EX-99.1) --- Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call Today at 5:00 pm ET ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”)”
Governance Changes
AYTU BIOPHARMA, INC: Approved a 1-for-20 reverse stock split via a Certificate of Amendment to the Certificate of Incorporation, effective January 6, 2023 (effective 2023-01-06).
“On January 4, 2023, the Board of Directors of Aytu BioPharma, Inc. (“the Company” or “Aytu”) approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective at 12:01 a.m. Eastern Time on Friday, January 6, 2023 pursuant to a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Certificate of Incorporation.”
Gary Cantrell departed as Member of the Board of Directors at AYTU BIOPHARMA, INC.
“On December 22, 2022, Gary Cantrell, a member of the Board of Directors of Aytu BioPharma, Inc. (the “Company”), notified the Company of his intention to retire from the Company's Board of Directors, effective December 31, 2022.”
Auditor Changes
AYTU BIOPHARMA, INC engaged Grant Thornton LLP as its auditor.
“On December 12, 2022, the Audit Committee appointed Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ended June 30, 2023.”
Auditor Changes
AYTU BIOPHARMA, INC dismissed Plante & Moran PLLC as its auditor.
“On December 12, 2022, the Audit Committee of the Board of Directors of Aytu BioPharma, Inc. (the “Company”) dismissed Plante & Moran PLLC (“Plante Moran”), as the Company’s independent registered public accounting firm.”
Listing & Compliance Notices
AYTU BIOPHARMA, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 22, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 22, 2023, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule under the Nasdaq Listing Rules, including enacting a reverse stock split. On October 5, 2022, the Company’s stockholders approved an amendment to its Cer”
Christopher Brooke was appointed as Chief Operating Officer at AYTU BIOPHARMA, INC.
“Effective November 14, 2022, Aytu BioPharma, Inc. (the “Company”) appointed Christopher Brooke as Chief Operating Officer”
Earnings Releases
AYTU BIOPHARMA, INC reported the first quarter of fiscal year 2023 ended September 30, 2022 results: revenue $27.7 million.
“Q1 2023 Commercial Highlights (3 months ending September 30, 2022) · Total net revenue was $27.7 million, a new quarterly record, and an increase of 26% over the $21.9 million in net revenue in the year ago quarter.”
Vivian Liu was appointed as Director at AYTU BIOPHARMA, INC.
“On June 24 2022, the Board of Directors of Aytu BioPharma, Inc. (the “Company”) appointed Vivian Liu to the Board of Directors, effective July 1, 2022.”
Mark Oki was appointed as Chief Financial Officer at AYTU BIOPHARMA, INC.
“On January 4, 2022, Aytu issued a press release announcing the appointment of Mr. Oki as Chief Financial Officer of the Company effective January 17, 2022.”
Richard I. Eisenstadt resigned as Chief Financial Officer at AYTU BIOPHARMA, INC.
“On December 8, 2021, Richard I. Eisenstadt resigned as Chief Financial Officer of Aytu BioPharma, Inc. (the “Company”), effective December 30, 2021, to pursue another opportunity at a development-stage pharmaceutical company.”
Steven J. Boyd resigned as member of the board of directors at AYTU BIOPHARMA, INC.
“On August 30, 2021, Steven J. Boyd resigned as a members of the board of directors of Aytu BioPharma, Inc. (the “Company”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.